Aligos Therapeutics (ALGS) Current Deferred Revenue (2020 - 2025)

Aligos Therapeutics (ALGS) has reported Current Deferred Revenue for 6 consecutive years, with $168000.0 the latest figure, recorded in Q3 2025.

• For the quarter ending Q3 2025, Current Deferred Revenue changed N/A year-over-year to $168000.0; the trailing twelve-month figure through Sep 2025 stood at $168000.0 (changed N/A YoY), and the FY2024 full-year result was $151000.0, down 88.46% from the prior year.
• Current Deferred Revenue fell to $168000.0 in Q3 2025 per ALGS's latest filing, from $579000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $15.1 million in Q1 2022 and bottomed at $151000.0 in Q4 2024.
• Historically, Current Deferred Revenue has averaged $6.1 million across 5 years, with a median of $6.6 million in 2021.
• The sharpest annual moves came in 2022 and 2024: Current Deferred Revenue jumped 98.75% in 2022, then sank 88.46% in 2024.
• Over 5 years, Current Deferred Revenue stood at $7.6 million in 2021, then climbed by 14.42% to $8.7 million in 2022, then tumbled by 85.04% to $1.3 million in 2023, then tumbled by 88.46% to $151000.0 in 2024, then grew by 11.26% to $168000.0 in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $168000.0, $579000.0, and $151000.0 for Q3 2025, Q2 2025, and Q4 2024 respectively.